Abstract Search

ea0099ep413 | Adrenal and Cardiovascular Endocrinology | ECE2024

Modified release hydrocortisone, a new treatment for congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a single center ‘real-world evidence’ preliminary study

Simeoli Chiara , M. Crescenzo Erminio , M. Pulci Doria Augusta , Larocca Angelica , Di Paola Nicola , Pivonello Claudia , Negri Mariarosaria , Colao Annamaria , Pivonello Rosario

Life-long glucocorticoid (GC) treatment is needed in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, to replace GC deficiency and to control androgens excess. Multiple daily immediate-release-hydrocortisone (IR-HC), characterized by GC overexposure, peaks and troughs, is frequently associated with a suboptimal androgen control, due to ACTH overnight increase. Once daily dual-release-HC (DR-HC), approved for adrenal insufficiency and, despit...

0 shares

Endocrine Abstracts

Modified release hydrocortisone, a new treatment for congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a single center ‘real-world evidence’ preliminary study

BiosciAbstracts